MicroRNA‑638 expression change in osteosarcoma patients via PLD1 and VEGF expression

Xue,Min; Shen,Jinhu; Cui,Jie; Wu,Jinxia; Qiao,Weili; Ding,Ningding; Song,Chengjie; Shan,Bin

doi:10.3892/etm.2019.7429

MicroRNA‑638 expression change in osteosarcoma patients via PLD1 and VEGF expression

Authors:
- Min Xue
- Jinhu Shen
- Jie Cui
- Jinxia Wu
- Weili Qiao
- Ningding Ding
- Chengjie Song
- Bin Shan
View Affiliations

Affiliations: Department of Physiology, Xuzhou Medical University, Xuzhou, Jiangsu 22100, P.R. China, Department of Orthopedics, Xuzhou City Hospital of Traditional Chinese Medicine, Xuzhou, Jiangsu, 221004, P.R. China, College of Medical Sciences, Washington State University, Spokane, WA 99201, USA
Published online on: March 22, 2019 https://doi.org/10.3892/etm.2019.7429
Pages: 3899-3906
Copyright: © Xue et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The present study aimed to investigate the function and mechanism of microRNA‑638 (miR‑638) in osteosarcoma. MiR‑638 expression change in patients with osteosarcoma was detected by reverse transcription‑quantitative polymerase chain reaction. Expression of miR‑638 was observed to be downregulated in patients with osteosarcoma compared with the control group. In vitro, overexpression of miR‑638 induced apoptosis, and inhibited cell proliferation and invasion of osteosarcoma cells. Overexpression of miR‑638 induced Bcl‑2 associated X and caspase‑3 protein expression, and suppressed cyclin D1, phospholipase D1 (PLD1) and vascular endothelial growth factor (VEGF) protein expression in osteosarcoma. The promotion of PLD1 decreased the effects of miR‑638 on osteosarcoma cell proliferation. In summary, it was demonstrated that miRNA‑638 expression change in patients with osteosarcoma and an in vitro model via PLD1 and VEGF expression and miRNA‑638 may be potential clinical indicators of osteosarcoma.

View Figures

View References

1	Morris CD, Teot LA, Bernstein ML, Marina N, Krailo MD, Villaluna D, Janeway KA, DuBois SG, Gorlick RG and Randall RL: Assessment of extent of surgical resection of primary high-grade osteosarcoma by treating institutions: A report from the children's oncology group. J Surg Oncol. 113:351–354. 2016. View Article : Google Scholar : PubMed/NCBI
2	Nataraj V, Batra A, Rastogi S, Khan SA, Sharma MC, Vishnubhatla S and Bakhshi S: Developing a prognostic model for patients with localized osteosarcoma treated with uniform chemotherapy protocol without high dose methotrexate: A single-center experience of 237 patients. J Surg Oncol. 112:662–668. 2015. View Article : Google Scholar : PubMed/NCBI
3	Xie L, Liao Y, Shen L, Hu F, Yu S, Zhou Y, Zhang Y, Yang Y, Li D, Ren M, et al: Identification of the miRNA-mRNA regulatory network of small cell osteosarcoma based on RNA-seq. Oncotarget. 8:42525–42536. 2017.PubMed/NCBI
4	Fujiwara T, Uotani K, Yoshida A, Morita T, Nezu Y, Kobayashi E, Yoshida A, Uehara T, Omori T, Sugiu K, et al: Clinical significance of circulating miR-25-3p as a novel diagnostic and prognostic biomarker in osteosarcoma. Oncotarget. 8:33375–33392. 2017. View Article : Google Scholar : PubMed/NCBI
5	Gai P, Sun H, Wang G, Xu Q, Qi X, Zhang Z and Jiang L: miR-22 promotes apoptosis of osteosarcoma cells via inducing cell cycle arrest. Oncol Lett. 13:2354–2358. 2017. View Article : Google Scholar : PubMed/NCBI
6	Zhang C, Long F, Wan J, Hu Y and He H: MicroRNA-205 acts as a tumor suppressor in osteosarcoma via targeting RUNX2. Oncol Rep. 35:3275–3284. 2016. View Article : Google Scholar : PubMed/NCBI
7	Xu M, Jin H, Xu CX, Sun B, Mao Z, Bi WZ and Wang Y: miR-382 inhibits tumor growth and enhance chemosensitivity in osteosarcoma. Oncotarget. 5:9472–9483. 2014. View Article : Google Scholar : PubMed/NCBI
8	Dai N, Qing Y, Cun Y, Zhong Z, Li C, Zhang S, Shan J, Yang X, Dai X, Cheng Y, et al: miR-513a-5p regulates radiosensitivity of osteosarcoma by targeting human apurinic/apyrimidinic endonuclease. Oncotarget. 9:25414–25426. 2016.PubMed/NCBI
9	He S, Xiao Z, Chen L and Xiong S: Comment on Xu XW et al: Prognostic significance of VEGF expression in osteosarcoma: A meta-analysis. Tumour Biol. 35:6193–6194. 2014. View Article : Google Scholar : PubMed/NCBI
10	Ohba T, Cates JM, Cole HA, Slosky DA, Haro H, Ando T, Schwartz HS and Schoenecker JG: Autocrine VEGF/VEGFR1 signaling in a subpopulation of cells associates with aggressive osteosarcoma. Mol Cancer Res. 12:1100–1111. 2014. View Article : Google Scholar : PubMed/NCBI
11	Cheng J, Chen Y, Zhao P, Liu X, Dong J, Li J, Huang C, Wu R and Lv Y: Downregulation of miRNA-638 promotes angiogenesis and growth of hepatocellular carcinoma by targeting VEGF. Oncotarget. 7:30702–30711. 2016.PubMed/NCBI
12	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
13	Kudawara I, Aoki Y, Ueda T, Araki N, Naka N, Nakanishi H, Matsumine A, Ieguchi M, Mori S, Myoui A, et al: Neoadjuvant and adjuvant chemotherapy with high-dose ifosfamide, doxorubicin, cisplatin and high-dose methotrexate in non-metastatic osteosarcoma of the extremities: A phase II trial in Japan. J Chemother. 25:41–48. 2013. View Article : Google Scholar : PubMed/NCBI
14	Zhao J, Xu H, He M, Wang Z and Wu Y: Rho GTPase-activating protein 35 rs1052667 polymorphism and osteosarcoma risk and prognosis. Biomed Res Int. 2014:3969472014. View Article : Google Scholar : PubMed/NCBI
15	Grignani G, Palmerini E, Ferraresi V, D'Ambrosio L, Bertulli R, Asaftei SD, Tamburini A, Pignochino Y, Sangiolo D, Marchesi E, et al: Sorafenib and everolimus for patients with unresectable high-grade osteosarcoma progressing after standard treatment: A non-randomised phase 2 clinical trial. Lancet Oncol. 16:98–107. 2015. View Article : Google Scholar : PubMed/NCBI
16	Lin CY, Tzeng HE, Li TM, Chen HT, Lee Y, Yang YC, Wang SW, Yang WH and Tang CH: WISP-3 inhibition of miR-452 promotes VEGF-A expression in chondrosarcoma cells and induces endothelial progenitor cells angiogenesis. Oncotarget. 8:39571–39581. 2017.PubMed/NCBI
17	Wang Z, Wen P, Luo X, Fang X, Wang Q, Ma F and Lv J: Association of the vascular endothelial growth factor (VEGF) gene single-nucleotide polymorphisms with osteosarcoma susceptibility in a Chinese population. Tumour Biol. 35:3605–3610. 2014. View Article : Google Scholar : PubMed/NCBI
18	Zhang C, Zhao Y and Zeng B: Enhanced chemosensitivity by simultaneously inhibiting cell cycle progression and promoting apoptosis of drug-resistant osteosarcoma MG63/DXR cells by targeting Cyclin D1 and Bcl-2. Cancer Biomark. 12:155–167. 2012. View Article : Google Scholar : PubMed/NCBI
19	Liu Y, Zheng Q, Wu H, Guo X, Li J and Hao S: Rapamycin increases pCREB, Bcl-2, and VEGF-A through ERK under normoxia. Acta Biochim Biophys Sin (Shanghai). 45:259–267. 2013. View Article : Google Scholar : PubMed/NCBI
20	Wang J, Ni J, Yi S, Song D and Ding M: Protein inhibitor of activated STAT xalpha depresses cyclin D and cyclin D kinase, and contributes to the inhibition of osteosarcoma cell progression. Mol Med Rep. 13:1645–1652. 2016. View Article : Google Scholar : PubMed/NCBI
21	Wu J, Cui LL, Yuan J, Wang Y and Song S: Clinical significance of the phosphorylation of MAPK and protein expression of cyclin D1 in human osteosarcoma tissues. Mol Med Rep. 15:2303–2307. 2017. View Article : Google Scholar : PubMed/NCBI
22	Li P, Liu Y, Yi B, Wang G, You X, Zhao X, Summer R, Qin Y and Sun J: MicroRNA-638 is highly expressed in human vascular smooth muscle cells and inhibits PDGF-BB-induced cell proliferation and migration through targeting orphan nuclear receptor NOR1. Cardiovasc Res. 99:185–193. 2013. View Article : Google Scholar : PubMed/NCBI